AAV mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
AssigneeThe United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsJohn A. Chiorini, Giovanni DiPasquale, Edoardo Mannucci
Life of this patent
Estimating the term…
Abstract
The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an AAV virion comprising an AAV vector that encodes an exendin-4 protein. Also provided are exendin-4 proteins and nucleic acid molecules that encode such exendin-4 proteins. Also provided are AAV vectors and AAV virions that encode an exendin-4 protein. One embodiment is an exendin-4 protein that is a fusion protein comprising an NGF secretory segment joined to the amino terminus of an exendin-4 protein domain.
Claims6
A method of preventing weight gain in a subject, the method comprising administering to a salivary gland of the subject an adeno-associated virus (AAV) virion comprising an AAV vector encoding a glucagon-like peptide-1(GLP-1) protein joined to a secretory segment.
Dependencies are inferred from the claim text.